EIF4EBP1 and glioma: Bisteric inhibitors combine allosteric binding with an ATP-competitive inhibitory mechanism (13) and more durably suppress mTORC1 outputs, including phosphorylation of 4EBP1, than do allosteric inhibitors in models of glioma (9).